What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse?
- 1 May 2010
- journal article
- review article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 8 (5) , 868-876
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Pulmonary hypertension is ameliorated in mice deficient in thrombin‐activatable fibrinolysis inhibitorJournal of Thrombosis and Haemostasis, 2010
- Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?Journal of Thrombosis and Haemostasis, 2009
- A Novel Function of Thrombin-activatable Fibrinolysis Inhibitor during Rat Liver Regeneration and in Growth-promoted Hepatocytes in Primary CultureJournal of Biological Chemistry, 2009
- Regulation of Chemerin Bioactivity by Plasma Carboxypeptidase N, Carboxypeptidase B (Activated Thrombin-activable Fibrinolysis Inhibitor), and PlateletsJournal of Biological Chemistry, 2009
- Thrombin Hydrolysis of Human Osteopontin Is Dependent on Thrombin Anion-binding ExositesJournal of Biological Chemistry, 2008
- Proteolytic cleavage of carboxypeptidase N markedly increases its antifibrinolytic activityJournal of Thrombosis and Haemostasis, 2008
- Fibrogenesis of Parenchymal OrgansProceedings of the American Thoracic Society, 2008
- Thrombin-activatable procarboxypeptidase B regulates activated complement C5a in vivoBlood, 2006
- Chronic pulmonary hypertension‐the monocrotaline model and involvement of the hemostatic systemJournal of Toxicology and Environmental Health, Part B, 1998
- An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunitsBiochemical and Biophysical Research Communications, 1989